Leukemia supplements最新文献_第2页

Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models. 小鼠骨髓增生性肿瘤的病理生理学和治疗。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.15

R A Van Etten

引用次数: 0

Harnessing alloreactivity to achieve anti-leukemic responses. 利用自体反应性实现抗白血病反应。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.6

L D Fast

引用次数: 0

The polycythemia vera stem cell. 真性红细胞增多症干细胞。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.13

J L Spivak

引用次数: 1

Altered microenvironmental regulation of CML stem cells. CML干细胞微环境调节的改变。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.1

R Bhatia

引用次数: 6

Myeloid differentiation and the leukemia-initiating cell. 骨髓分化与白血病起始细胞。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.14

D G Tenen

引用次数: 2

Dissecting reprogramming, differentiation and conversion with network biology. 利用网络生物学剖析重编程、分化和转换。

Leukemia supplements Pub Date : 2014-12-01 Epub Date: 2014-12-17 DOI: 10.1038/leusup.2014.2

G Q Daley

引用次数: 0

Advances in current treatment for patients with newly diagnosed multiple myeloma. 新诊断多发性骨髓瘤患者的当前治疗进展

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.1

S Lonial

引用次数: 1

Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation. 优化符合移植条件的新诊断多发性骨髓瘤患者的预后。

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.4

P Moreau, C Touzeau

{"title":"Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.","authors":"P Moreau, C Touzeau","doi":"10.1038/leusup.2013.4","DOIUrl":"https://doi.org/10.1038/leusup.2013.4","url":null,"abstract":"High-dose therapy with autologous stem cell transplantation (HDT-ASCT) has been considered to be the standard frontline treatment for younger, fit patients with multiple myeloma (MM) since the 1990s. Efforts continue to optimize the use of HDT-ASCT with the aim of improving outcomes. One strategy has been the incorporation of novel agents (thalidomide, lenalidomide and bortezomib) in the pre-transplantation setting as an induction therapy or in the post-transplantation setting as a consolidation or maintenance therapy. Given their high response rates, three-drug induction therapy regimens (for example, bortezomib-thalidomide-dexamethasone, lenalidomide-bortezomib-dexamethasone and cyclophosphamide-bortezomib-dexamethasone) are now the standard of care. Thalidomide and bortezomib are well suited for consolidation therapy, and regimens using these agents can improve the depth of response following HDT-ASCT. Lenalidomide is particularly well suited for long-term maintenance therapy following HDT-ASCT, and initial results are promising and have shown improvements in disease outcomes such as progression-free survival and overall survival in some cases, although a low incidence of second primary malignancies have been observed. Further studies are needed to determine the optimal regimen and duration of induction therapy, the impact of maintenance on overall survival and the safety of long-term treatment. Many of the studies currently underway in MM will help address these aspects. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"2 Suppl 1","pages":"S15-20"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2013.4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34480549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. 不适合自体干细胞移植的新诊断多发性骨髓瘤患者的治疗进展。

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.5

J F San Miguel, M-V Mateos

{"title":"Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.","authors":"J F San Miguel, M-V Mateos","doi":"10.1038/leusup.2013.5","DOIUrl":"https://doi.org/10.1038/leusup.2013.5","url":null,"abstract":"The majority of newly diagnosed multiple myeloma patients are over 65 years and/or physically unfit, and, therefore, are not eligible for standard treatment with high-dose chemotherapy and stem cell transplantation. The treatment goals in these patients should be to ensure improvement in disease management and to prolong survival while ensuring quality of life. Until recently, treatment options for such patients were limited, but new treatment combinations based on the novel agents thalidomide, bortezomib and lenalidomide have improved outcomes and survival. Moreover, phase III data indicate that maintenance treatment with novel agents may contribute to extended progression-free survival; however, the optimal duration of long-term therapy has not yet been defined. The potential for novel treatment regimens to improve the adverse prognosis associated with high-risk cytogenetic profiles, such as deletion 17p, also requires further research. Elderly patients, particularly those over 75 years and the clinically vulnerable, require close monitoring and individualized, dose-modified regimens to improve tolerability and treatment efficacy, while maintaining quality of life. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"2 Suppl 1","pages":"S21-7"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2013.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34480550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma. 结论:新近诊断的多发性骨髓瘤的治疗进展。

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.6

S Lonial

引用次数: 0